Dai Dannie, Feyman Yevgeniy, Figueroa Jose F, Frakt Austin B, Garrido Melissa M
Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Washington, D.C., USA.
J Gen Intern Med. 2025 Feb;40(2):412-419. doi: 10.1007/s11606-024-08938-w. Epub 2024 Jul 19.
Medicare beneficiaries are increasingly enrolling in Medicare Advantage (MA), which employs a wide range of practices around restriction of the networks of providers that beneficiaries visit. Though Medicare beneficiaries highly value provider choice, it is unknown whether the MA contract quality metrics which beneficiaries use to inform their contract selection capture the restrictiveness of contracts' provider networks.
We evaluated whether there are meaningful associations between provider network restrictiveness (across primary care, psychiatry, and endocrinology providers) and contracts' overall star quality rating, as well as between network restrictiveness and contracts' performance on access to care measures from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey.
Medicare Advantage contracts with health maintenance organization (HMO), local preferred provider organization (PPO), and point of service (POS) plans with available data.
A cross-sectional analysis using multivariable linear regressions to assess the relationship between provider network restrictiveness and contract quality scores in 2013 through 2017.
Statistical significance in the relationship between network restrictiveness and contract performance on quality measures.
Across all study years, we included 562 unique contracts and 2801 contract-years. We find no evidence of consistent relationships between MA physician network restrictiveness and contract star rating. For primary care, psychiatry, and endocrinology, respectively, a 10 percentage point increase in restrictiveness was associated with a 0.02 (95% confidence interval [CI] -0.01 to 0.04), 0.0008 (95% CI, -0.01 to 0.02), and -0.01 (95% CI, -0.01 to 0.001) difference in star rating (p-value > 0.05 for all). Similarly, we find no evidence of consistent relationships between network restrictiveness and access to care measures.
Our findings suggest that existing MA contract quality measures are not useful for indicating differences in network restrictiveness. Given the importance of provider choice to beneficiaries, more specific metrics may be needed to facilitate informed decisions about MA coverage.
医疗保险受益人越来越多地加入医疗保险优势计划(MA),该计划围绕限制受益人就诊的医疗服务提供者网络采用了广泛的做法。尽管医疗保险受益人高度重视医疗服务提供者的选择,但尚不清楚受益人用于指导其合同选择的MA合同质量指标是否反映了合同医疗服务提供者网络的限制性。
我们评估了医疗服务提供者网络的限制性(涵盖初级保健、精神病学和内分泌学提供者)与合同的整体星级质量评级之间是否存在有意义的关联,以及网络限制性与合同在《医疗服务提供者和系统消费者评估》(CAHPS)调查中的就医措施表现之间是否存在关联。
与健康维护组织(HMO)、当地优选提供者组织(PPO)以及具有可用数据的服务点(POS)计划签订的医疗保险优势合同。
采用多变量线性回归进行横断面分析,以评估2013年至2017年医疗服务提供者网络限制性与合同质量得分之间的关系。
网络限制性与质量指标方面合同表现之间关系的统计学显著性。
在所有研究年份中,我们纳入了562份独特合同和2801个合同年。我们没有发现MA医生网络限制性与合同星级评级之间存在一致关系的证据。对于初级保健、精神病学和内分泌学,限制性分别增加10个百分点,星级评级差异分别为0.02(95%置信区间[CI] -0.01至0.04)、0.0008(95%CI,-0.01至0.02)和-0.01(95%CI,-0.01至0.001)(所有p值均>0.05)。同样,我们没有发现网络限制性与就医措施之间存在一致关系的证据。
我们的研究结果表明,现有的MA合同质量衡量标准对于表明网络限制性差异并无用处。鉴于医疗服务提供者选择对受益人的重要性,可能需要更具体的指标来促进关于MA保险范围的明智决策。